Inova plays a key role in trial of innovative treatment for tricuspid valve regurgitation that is now approved by the FDA

By InovaNewsroom | April 17, 2024 |

Update as of April 24, 2024: Inova’s structural heart team has now completed the first case in the Washington, DC region since the FDA approved a new device to treat tricuspid regurgitation (TR). Inova Schar Heart and Vascular’s Structural Heart/Valve Disease Program was among the top enrollers in the TRILUMINATE™ Pivotal Trial demonstrating the safety…

Read More

Inova’s Minimally Invasive Surgical Options Help Patients with Heart Valve Disease

By Eric Sarin, MD | February 14, 2022 |

Eric L. Sarin, MD, is a cardiac and thoracic surgeon with Inova Heart and Vascular Institute (IHVI). He is Section Chief of Adult Cardiac Surgery, Co-Director of the Structural Heart and Valve Program and Co-Director of Cardiovascular Research.  Matthew W. Sherwood, MD, MHS, is an Inova interventional cardiologist, Director of Inova’s Left Atrial Appendage Closure/WATCHMAN…

Read More